Short answer
Biomarin Pharmaceutical Inc (BMRN) filed an 8-K current report with the SEC on October 6, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Alesta acquisition expected to add approximately $283 million of pre-tax IPR&D expense in Q3 2026.
Biomarin Pharmaceutical Inc 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Alesta acquisition expected to add approximately $283 million of pre-tax IPR&D expense in Q3 2026
- Q3 GAAP and Non-GAAP diluted EPS impact: approximately $1.50 unfavorable
- Full-year 2026 Alesta charges estimated at approximately $320 million, including operating, transaction and transition costs
- Full-year GAAP and Non-GAAP diluted EPS impact: approximately $1.55 unfavorable
- Updated 2026 guidance expected with Q3 results, while preliminary estimates remain subject to closing procedures
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Biomarin Pharmaceutical Inc 8-K filings
Get the next BMRN 8-K as it lands
Follow BMRN for push alerts, or ask the research agent what this filing means.